Home / Drug shortages / Insulin Aspart Injection

Insulin Aspart Injection — FDA Drug Shortage

To Be Discontinued — Novo Nordisk, Inc.

The FDA lists a drug shortage record for Insulin Aspart Injection (injection) from Novo Nordisk, Inc. with status To Be Discontinued. The shortage was first posted on 07/21/2025.

Shortage Details

Status
To Be Discontinued
Company
Novo Nordisk, Inc.
Package NDC
73070-103-15
Dosage Form
Injection
Presentation
Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen® (NDC 73070-103-15)
Initial Posting
07/21/2025
Revised Date

FDA data resources